Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
08:00am, Tuesday, 25'th Mar 2025
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
08:00am, Tuesday, 18'th Mar 2025
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #1
PDS Biotech Leadership to Participate in March Conferences
08:00am, Tuesday, 11'th Mar 2025
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
08:45am, Friday, 07'th Mar 2025
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
EMV Capital portfolio company PDS Biotechnology raises $11mln
03:34am, Friday, 28'th Feb 2025
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.3
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Thursday, 27'th Feb 2025
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkp
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
08:00am, Monday, 24'th Feb 2025
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
08:00am, Thursday, 20'th Feb 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Dec 2024
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
08:00am, Tuesday, 03'rd Dec 2024
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prev
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
10:35am, Wednesday, 20'th Nov 2024
The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street a
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
11:18am, Thursday, 14'th Nov 2024
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer
EMV Capital highlights progress update from portfolio company PDS Biotech
11:03am, Thursday, 14'th Nov 2024
EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said: "Since our las
